Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here we present a protocol to study the in vivo localization of antibodies in mice tumor xenograft models.

Abstract

Monoclonal antibodies are high affinity multifunctional drugs that work by variable independent mechanisms to eliminate cancer cells. Over the last few decades, the field of antibody-drug conjugates, bispecific antibodies, chimeric antigen receptors (CAR) and cancer immunotherapy has emerged as the most promising area of basic and therapeutic investigations. With numerous successful human trials targeting immune checkpoint receptors and CAR-T cells in leukemia and melanoma at a breakthrough pace, it is highly exciting times for oncologic therapeutics derived from variations of antibody engineering. Regrettably, a significantly large numbers of antibody and CAR based therapeutics have also proven disappointing in human trials of solid cancers because of the limited availability of immune effector cells in the tumor bed. Importantly, nonspecific distribution of therapeutic antibodies in tissues other than tumors also contribute to the lack of clinical efficacy, associated toxicity and clinical failure. As faithful translation of preclinical studies into human clinical trails are highly relied on mice tumor xenograft efficacy and safety studies, here we highlight a method to test the tumor and general tissue distribution of therapeutic antibodies. This is achieved by labeling the protein-A purified antibody with near Infrared fluorescent dye followed by live imaging of tumor bearing mice.

Introduction

FDA approved the first monoclonal antibody targeting CD3 (OKT3, Muromonab) in 19861,2. Since then for the next twenty years, there has been a rapid explosion in the field of antibody engineering due to the overwhelming success of antibodies against immune checkpoint inhibitors3. Beside indirect activation of immune system, antibodies are being aimed to directly flag cancer cells to precisely engage immune effector cells, trigger cytotoxicity via death receptor agonist, block tumor cell survival signaling, obstruct angiogenesis (growth of blood vessels), constrain immune checkpoint regul....

Protocol

All the procedures involving animals handling and tumor xenografts studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) here at the University of Virginia and conform to the relevant regulatory standards

1. Expression and purification of antibodies

  1. Maintenance of CHO cells
    1. Grow CHO cells in FreeStyle CHO Media supplemented with commercially available 1x glutamine supplement at 37 ËšC shaking at 130 rpm with 5% CO2 .......

Representative Results

In the described methodology, first we cloned antibodies targeting folate receptor alpha-1 (FOLR1) named farletuzumab, and a bispecific antibody called BaCa consisting of farletuzumab and lexatumumab along with control antibodies such as abagovomab (sequences provided in Supplementary File 1). Details of representative variable heavy (VH) and variable light (VL) domains in DNA clones (pVH, pVL) are shown in Figure 1A. To confirm the positive clones, we carried out colony PCR.......

Discussion

Selective and tumor tissue specific delivery of anti-cancer therapeutic agent is the key to measure efficacy and safety of a given targeted therapy13. Here we have described a quick and efficient approach to investigate the detailed tissue and tumor distribution of clinical, farletuzumab and a nonclinical BaCa antibody. The described approach is applicable to any newly generated antibody and can be used alongside of a clinically effective antibody (with desired qualities) for its tumor/organ distr.......

Acknowledgements

We are thankful to University of Virginia Cancer Center Core Imaging Facility, Biomolecular Analysis Facility, Advanced Microscopy Facility and the Core Vivarium Facility for Assistance. J. T-S is an early career investigator of Ovarian Cancer Academy (OCA-DoD). This work was supported by NCI/NIH grant (R01CA233752) to J. T-S, U.S. DoD Breast Cancer Research Program (BCRP) breakthrough level-1 award to J. T-S (BC17097) and U.S. DoD Ovarian Cancer Research Program (OCRP) funding award (OC180412) to J. T-S

....

Materials

NameCompanyCatalog NumberComments
FreeStyle CHO mediaGibco Life TechnologiesCat # 12651-014
Anti-Anti (100X)Gibco Life TechnologiesCat # 15240-062
Anti-Clumping AgentGibco Life TechnologiesCat # 01-0057DG
BD Insulin SyringeBD BioSciencesCat #329420
Caliper IVIS SpectrumPerkinElmerCat #124262
CHO CD EfficientFeed BGibco Life TechnologiesCat #A10240-01
Corning 500 mL DMEM (Dulbecco's Modified Eagle's Medium)CorningCat # 10-13-CV
Corning 500 mL RPMI 1640CorningCat # 10-040-CV
Cy5 conjugated Anti-Human IgG (H+L)Jackson ImmunoResearchCat # 709-175-149
GlutaMax-I (100X)Gibco Life TechnologiesCat # 35050-061
HiPure Plasmid Maxiprep kitInvitrogenCat # K21007
HiTrap MabSelect SuRe ColumnGE HealthcareCat # 11-0034-93
InfusionTakara BioScienceSTO344
IRDye 800CW NHS EsterLI-CORCat # 929-70020
Isoflurane, USPCovetrusCat # 11695-6777-2
Lubricant Eye OintmentRefresh Lacri-LubeCat #4089
MatrigelCorningCat # 354234
PEI transfection reagentThermo FisherCat # BMS1003A
Slide-A-Lyzer Dialysis CassettesThermo ScientificCat # 66333
Steritop Vacuum FiltersMillipore ExpressCat #S2GPT02RE
Trypsin-EDTAGibco Life TechnologiesCat # 15400-054
Experimental Models: Cell lines
Human: OVCAR-3American Type Culture CollectionATCC HTB-161
Human: CHO-K cellsStable transformed in our labATCC CCL-61
Mouse: 4T1Kind gift from Dr. Chip Landen, UVA
Mouse: MC38Kind gift from Dr. Suzanne Ostrand-Rosenberg, UMBCAuthenticated by STR profiling
Mouse: MC38 hFOLR1Generated in our laboratory (This paper)
Experimental Models: Animal
Mice: athymic Nude Foxn1nu/Foxn1+EnvigoMultiple Orders
Mice: NOD.Cg Prkdcscid Il2rgtm1Wjl/SzJJackson LaboratoryMultiple Orders

References

  1. Takahashi, K. Muromonab CD3 (Orthoclone OKT3). Journal of Toxicological Sciences. 20, 483-484 (1995).
  2. Tushir-Singh, J. Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. Expert Opi....

Explore More Articles

Antibody DistributionTumor LocalizationTissue DistributionAntibody ScreeningCHO Cell ExpressionAntibody PurificationProtein A ColumnReal time MonitoringSPECTPETCost effective Technique

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved